01—Abstract
Summary
Summary of the 8-K filed December 5, 2025. Cited figures are marked; the original filing is the authoritative source.
On December 4, 2025, Natera, Inc. completed its acquisition of Foresight Diagnostics Inc., a privately held cancer diagnostics company and CLIA-registered laboratory specializing in molecular residual disease (MRD) detection in B-cell lymphomas, under a Merger Agreement dated October 10, 2025.
Natera agreed to issue 1,127,982 shares of common stock to Foresight's stockholders as consideration, plus an estimated 824,583 Potentially Issuable Shares that may become issuable over the next three years through escrow releases, milestones, post-closing price adjustments, and a price protection formula. The shares are being issued without registration under the Securities Act in reliance on Section 4(a)(2), and Natera intends to file a Form S-3 for resale of these shares. According to the accompanying press release (Exhibit 99.1), the transaction is an all-stock deal with a $275 milliona upfront payment and an additional $175 million in earnouts tied to revenue and reimbursement milestones.
The company says the acquisition adds Foresight's PhasED-Seq phased variant technology, which Foresight reports achieves LOD95 of 0.3 parts per million, to Natera's Signatera platform, and strengthens its presence in lymphoma, where Foresight's data supported the inclusion of ctDNA MRD in NCCN guidelines for diffuse large B-cell lymphoma. The enhanced phased-variant Signatera version is available for research use now and is expected to launch clinically in 2026.
The filing also notes forward-looking risks, including integration of Foresight, realization of anticipated benefits, reimbursement coverage, and the dilutive effect and trading-price sensitivity of the potentially issuable shares. Natera also plans 15 abstracts, including seven oral presentations, at the ASH Annual Meeting beginning December 6.
02—Key points
Key Highlights
- Natera closed its acquisition of Foresight Diagnostics on December 4, 2025, under an October 10, 2025 Merger Agreement.
- Consideration includes 1,127,982 shares of common stock issued at closing plus an estimated 824,583 Potentially Issuable Shares over the next three years.
- The press release describes the deal as all-stock, with a $275 million upfront payment and up to $175 million in earnouts tied to revenue and reimbursement milestones.
- Foresight's PhasED-Seq technology reports LOD95 of 0.3 ppm and detection below 0.1 ppm, which Natera plans to integrate into its Signatera platform.
- Enhanced Signatera with phased variants is available now for research use and is expected to launch clinically in 2026.
- Foresight's CLARITY MRD assay for lymphoma is used in three prospective MRD-driven clinical trials, and Foresight data supported ctDNA MRD inclusion in NCCN guidelines for diffuse large B-cell lymphoma.
- The shares were issued under the Section 4(a)(2) private placement exemption, with a planned Form S-3 resale registration.
03—Questions
Frequently Asked Questions
How much is Natera paying for Foresight Diagnostics?
The press release describes an all-stock transaction with a $275 million upfront payment and an additional $175 million in earnouts tied to revenue- and reimbursement-based milestones. The 8-K itself specifies 1,127,982 shares issued at closing plus an estimated 824,583 Potentially Issuable Shares.
Could the number of shares issued to Foresight stockholders increase?
Yes. The 824,583 Potentially Issuable Shares are an estimate and may be issued depending on escrow releases, milestone achievement, post-closing purchase price adjustments, and a price protection formula. The filing states the estimate is not a prediction of the final number and depends on factors including the future trading price of the common stock.
Why is Natera acquiring Foresight?
According to the press release, Foresight adds phased variant technology and a leading clinical position in lymphoma to Natera's MRD portfolio. The company says this will strengthen Signatera's performance across solid tumors and accelerate MRD adoption in lymphoma.
Are the newly issued shares registered for sale?
No. The shares were not initially registered under the Securities Act, and Natera relied on the Section 4(a)(2) exemption. The company intends to file an automatically effective Form S-3 to register the shares for resale.
When will the phased variant version of Signatera be available to clinicians?
The enhanced Signatera with phased variants is available now for research use by biopharma and academic partners. Natera expects to launch it for clinical use in 2026.
04—Continue